Due to procedural and technical advantages of liquid biopsy, it has been widely accepted as an alternative to tumor tissue genotyping for detecting EGFR mutations in NSCLC (Paweletz et al. 2016; Leighl et al. 2019; Rolfo et al. 2021; Raez et al. 2023). This evidence concerns the gene EGFR and non-small cell lung carcinoma.